UOC
BCRX icon

UBS O'Connor’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS O'Connor’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,630
Closed -$166K – 551
2024
Q1 		$166K Sell
32,630
-27,529
-46% -$155K ﹤0.01% 408
2023
Q4 		$360K Sell
60,159
-181,661
-75% -$1.05M 0.01% 379
2023
Q3 		$1.71M Buy
241,820
+9,357
+4% +$67.2K 0.03% 263
2023
Q2 		$1.64M Buy
232,463
+6,699
+3% +$53.8K 0.03% 328
2023
Q1 		$1.88M Buy
+225,764
New +$2.17M 0.04% 332
2022
Q4 		– Sell
-216,327
Closed -$2.73M – 51
2022
Q3 		$2.73M Sell
216,327
-20,000
-8% -$257K 0.03% 467
2022
Q2 		$2.5M Buy
+236,327
New +$2.44M 0.03% 603

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS O'Connor's BCRX Position: Q2 2024 in Review

UBS O'Connor sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 32,630 shares — an estimated $166K sold.

UBS O'Connor first reported a position in BCRX in Q2 2022 and held it in 7 quarters. The position peaked at $2.73M in Q3 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • UBS O'Connor reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 32,630 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $166K.
  • UBS O'Connor first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • UBS O'Connor's BioCryst Pharmaceuticals position peaked at $2.73M in Q3 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.